TDMS Study 55301-04 Pathology Tables
NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 CORE STUDY Facility: TSI Mason Research Chemical CAS #: 110-86-1 Lock Date: None Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Natural Death 12 12 21 11 Accidently Killed 3 6 4 5 Moribund Sacrifice 3 2 3 5 Survivors Terminal Sacrifice 32 30 22 29 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Esophagus (50) (50) (50) (50) Gallbladder (37) (40) (33) (34) Intestine Large, Rectum (44) (48) (47) (47) Intestine Large, Cecum (44) (49) (40) (45) Leiomyosarcoma 1 (2%) Intestine Small, Jejunum (42) (47) (38) (43) Intestine Small, Ileum (43) (48) (37) (41) Carcinoma 1 (2%) Liver (49) (50) (50) (50) Hemangioma 1 (2%) Hepatoblastoma 1 (2%) 2 (4%) 6 (12%) 12 (24%) Hepatoblastoma, Multiple 3 (6%) 4 (8%) Hepatocellular Carcinoma 10 (20%) 12 (24%) 19 (38%) 11 (22%) Hepatocellular Carcinoma, Multiple 3 (6%) 11 (22%) 14 (28%) 30 (60%) Hepatocellular Adenoma 13 (27%) 5 (10%) 6 (12%) 4 (8%) Hepatocellular Adenoma, Multiple 24 (49%) 34 (68%) 37 (74%) 30 (60%) Histiocytic Sarcoma 1 (2%) 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Mesentery (17) (18) (13) (13) Hepatoblastoma, Metastatic, Liver 1 (8%) 1 (8%) Histiocytic Sarcoma 2 (11%) Lipoma 1 (6%) Sarcoma 2 (11%) Pancreas (49) (49) (47) (48) Histiocytic Sarcoma 2 (4%) Sarcoma, Metastatic, Mesentery 1 (2%) Salivary Glands (50) (50) (49) (50) Schwannoma Malignant, Metastatic, Skin 1 (2%) Stomach, Forestomach (49) (49) (49) (49) Squamous Cell Papilloma 1 (2%) Stomach, Glandular (48) (49) (48) (49) ____________________________________________________________________________________________________________________________________ Page 2 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Blood Vessel (48) (47) (47) (47) Aorta, Histiocytic Sarcoma 1 (2%) Heart (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (49) (50) (48) (50) Carcinoma, Multiple 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Capsule, Adenoma 1 (2%) Islets, Pancreatic (49) (50) (47) (49) Adenoma 1 (2%) 2 (4%) Pituitary Gland (47) (44) (42) (46) Pars Distalis, Adenoma 8 (17%) 9 (20%) 6 (14%) 2 (4%) Thyroid Gland (50) (50) (50) (50) Follicular Cell, Adenoma 3 (6%) 2 (4%) 3 (6%) 3 (6%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (2) Hepatoblastoma, Metastatic, Liver 1 (50%) Tissue NOS (2) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (50%) Hepatoblastoma, Metastatic, Liver 1 (50%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (47) (48) (48) (45) Ovary (47) (49) (46) (49) Cystadenoma 4 (9%) 3 (6%) 1 (2%) Granulosa Cell Tumor Benign 1 (2%) 1 (2%) Hemangioma 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Oviduct (1) Schwannoma Malignant, Metastatic, Skin 1 (100%) Uterus (48) (50) (47) (50) Adenoma 1 (2%) Page 3 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Histiocytic Sarcoma 1 (2%) Polyp Stromal 2 (4%) 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (49) (50) (49) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) Lymph Node (10) (10) (7) (7) Iliac, Histiocytic Sarcoma 1 (10%) 1 (10%) Iliac, Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (10%) Mediastinal, Sarcoma, Metastatic, Mesentery 1 (10%) Mediastinal, Sarcoma, Metastatic, Skin 1 (10%) Pancreatic, Hepatoblastoma, Metastatic, Liver 1 (14%) Pancreatic, Sarcoma, Metastatic, Mesentery 1 (10%) Lymph Node, Mandibular (48) (50) (49) (47) Histiocytic Sarcoma 2 (4%) 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Schwannoma Malignant, Metastatic, Skin 1 (2%) Lymph Node, Mesenteric (48) (47) (43) (45) Hemangioma 1 (2%) Hepatoblastoma, Metastatic, Liver 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) 2 (4%) Spleen (49) (50) (48) (49) Histiocytic Sarcoma 1 (2%) 1 (2%) Thymus (45) (44) (46) (39) Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (49) (50) (50) (50) Squamous Cell Papilloma 1 (2%) 1 (2%) Subcutaneous Tissue, Hemangioma 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Sarcoma 2 (4%) 2 (4%) 3 (6%) 4 (8%) Subcutaneous Tissue, Schwannoma Malignant 1 (2%) 1 (2%) 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (1) (1) (1) Hepatoblastoma, Metastatic, Liver 1 (100%) Rhabdomyosarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) (50) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (50) Alveolar/Bronchiolar Adenoma 1 (2%) 3 (6%) 3 (6%) Alveolar/Bronchiolar Adenoma, Multiple 1 (2%) Alveolar/Bronchiolar Carcinoma 2 (4%) 1 (2%) 2 (4%) 3 (6%) Carcinoma, Metastatic, Harderian Gland 1 (2%) Hepatoblastoma, Metastatic, Liver 1 (2%) 3 (6%) Hepatocellular Carcinoma, Metastatic, Liver 2 (4%) 6 (12%) 10 (20%) Histiocytic Sarcoma 1 (2%) 1 (2%) Rhabdomyosarcoma, Metastatic, Skeletal Muscle 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Sarcoma, Metastatic, Skin 2 (4%) Schwannoma Malignant, Metastatic, Skin 1 (2%) Mediastinum, Alveolar/Bronchiolar Carcinoma, Metastatic, Lung 1 (2%) Mediastinum, Sarcoma, Metastatic, Skin 1 (2%) Mediastinum, Schwannoma Malignant, Metastatic, Skin 1 (2%) Nose (50) (50) (47) (50) Sarcoma 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Trachea (50) (50) (50) (50) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (1) (1) (1) Adenoma 1 (100%) Carcinoma 1 (100%) 1 (100%) ____________________________________________________________________________________________________________________________________ Page 5 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (49) (50) (49) (49) Histiocytic Sarcoma 1 (2%) 1 (2%) Schwannoma Malignant, Metastatic, Skin 1 (2%) Urinary Bladder (45) (49) (44) (43) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 2 (4%) 2 (4%) Leukemia Granulocytic 1 (2%) Lymphoma Malignant 6 (12%) 7 (14%) 4 (8%) 6 (12%) Mesothelioma Malignant 2 (4%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 6 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE 0 PPM 125 PPM 250 PPM 500 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 47 45 45 45 Total Primary Neoplasms 90 105 108 122 Total Animals with Benign Neoplasms 40 41 43 36 Total Benign Neoplasms 61 63 55 45 Total Animals with Malignant Neoplasms 26 30 40 44 Total Malignant Neoplasms 29 42 53 77 Total Animals with Metastatic Neoplasms 5 3 10 12 Total Metastatic Neoplasm 6 14 21 15 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 7 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Natural Death 11 18 11 11 Accidently Killed 2 1 1 3 Moribund Sacrifice 2 3 3 1 Survivors Natural Death 1 Terminal Sacrifice 35 28 34 35 Animals Examined Microscopically 50 50 49 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Small, Duodenum (43) (44) (43) (44) Intestine Small, Jejunum (40) (46) (42) (44) Carcinoma 1 (2%) Histiocytic Sarcoma 1 (2%) Liver (50) (50) (49) (50) Hemangioma 1 (2%) Hemangiosarcoma 1 (2%) Hemangiosarcoma, Multiple 2 (4%) Hepatoblastoma 1 (2%) 14 (28%) 16 (33%) 13 (26%) Hepatoblastoma, Multiple 1 (2%) 4 (8%) 6 (12%) 2 (4%) Hepatocellular Carcinoma 12 (24%) 16 (32%) 15 (31%) 22 (44%) Hepatocellular Carcinoma, Multiple 3 (6%) 19 (38%) 26 (53%) 18 (36%) Hepatocellular Adenoma 13 (26%) 11 (22%) 5 (10%) 11 (22%) Hepatocellular Adenoma, Multiple 16 (32%) 29 (58%) 29 (59%) 28 (56%) Hepatocholangiocarcinoma, Multiple 1 (2%) Histiocytic Sarcoma 1 (2%) 2 (4%) Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Mesentery (2) (7) (6) (4) Hepatocholangiocarcinoma, Metastatic, Liver 1 (14%) Histiocytic Sarcoma 1 (14%) Sarcoma 1 (14%) 1 (17%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (25%) Pancreas (49) (50) (48) (50) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Stomach, Forestomach (49) (50) (48) (49) Squamous Cell Papilloma 1 (2%) Page 8 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Stomach, Glandular (49) (50) (48) (47) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (49) (50) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (49) (49) (49) (49) Adenoma 1 (2%) 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Capsule, Adenoma 2 (4%) Capsule, Sarcoma, Metastatic, Mesentery 1 (2%) Capsule, Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Adrenal Medulla (48) (48) (49) (49) Pheochromocytoma Benign 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Islets, Pancreatic (49) (50) (48) (50) Adenoma 1 (2%) 2 (4%) 1 (2%) Thyroid Gland (49) (50) (49) (50) Follicular Cell, Adenoma 2 (4%) 2 (4%) 1 (2%) 2 (4%) Follicular Cell, Adenoma, Multiple 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (1) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (100%) Tissue NOS (1) Thoracic, Hemangiosarcoma 1 (100%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Coagulating Gland (1) Sarcoma, Metastatic, Mesentery 1 (100%) Epididymis (50) (50) (49) (50) Sarcoma 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Page 9 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Preputial Gland (50) (50) (49) (49) Sarcoma, Metastatic, Mesentery 1 (2%) Prostate (50) (48) (48) (49) Sarcoma, Metastatic, Mesentery 1 (2%) Seminal Vesicle (49) (49) (49) (50) Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Testes (50) (50) (49) (50) Sarcoma, Metastatic, Mesentery 1 (2%) 1 (2%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (49) (50) (49) (50) Hemangiosarcoma 1 (2%) Hemangiosarcoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%) Lymph Node (2) (4) (4) (2) Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver 1 (25%) Mediastinal, Sarcoma, Metastatic, Mesentery 1 (25%) 1 (25%) Mediastinal, Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (50%) Lymph Node, Mandibular (48) (47) (48) (50) Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%) Squamous Cell Carcinoma, Metastatic, Skin 1 (2%) Lymph Node, Mesenteric (43) (47) (44) (50) Hemangioma 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Spleen (49) (50) (47) (49) Hemangiosarcoma 1 (2%) 3 (6%) 1 (2%) 1 (2%) Hemangiosarcoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Thymus (46) (46) (39) (47) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Mesentery 1 (3%) ____________________________________________________________________________________________________________________________________ Page 10 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (49) (50) (48) (50) Squamous Cell Carcinoma 1 (2%) Subcutaneous Tissue, Basal Cell Adenoma 1 (2%) Subcutaneous Tissue, Hemangioma 1 (2%) 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) Subcutaneous Tissue, Mast Cell Tumor Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (3) (2) (1) Hepatoblastoma, Metastatic, Liver 1 (33%) Sarcoma, Metastatic, Mesentery 1 (33%) 1 (50%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (100%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (49) (50) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (49) (50) (49) (50) Alveolar/Bronchiolar Adenoma 10 (20%) 5 (10%) 7 (14%) 6 (12%) Alveolar/Bronchiolar Adenoma, Multiple 2 (4%) 1 (2%) 2 (4%) Alveolar/Bronchiolar Carcinoma 1 (2%) 2 (4%) 1 (2%) 1 (2%) Hemangiosarcoma, Metastatic, Liver 1 (2%) Hepatoblastoma, Metastatic, Liver 4 (8%) 7 (14%) 3 (6%) Hepatocellular Carcinoma, Metastatic, Liver 7 (14%) 7 (14%) 11 (22%) 13 (26%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Histiocytic Sarcoma 1 (2%) Mediastinum, Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Mediastinum, Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Nose (50) (49) (49) (50) ____________________________________________________________________________________________________________________________________ Page 11 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (5) (1) Adenoma 3 (60%) 1 (100%) Carcinoma 2 (40%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (49) (50) (48) (50) Hemangiosarcoma, Metastatic, Tissue NOS 1 (2%) Histiocytic Sarcoma 1 (2%) Mast Cell Tumor Malignant, Metastatic, Skin 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Renal Tubule, Adenoma 1 (2%) 1 (2%) Urinary Bladder (48) (49) (44) (50) Hemangioma 1 (2%) Squamous Cell Carcinoma, Metastatic, Uncertain Primary Site 1 (2%) Transitional Epithelium, Papilloma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(49) *(50) Histiocytic Sarcoma 1 (2%) 2 (4%) 1 (2%) Lymphoma Malignant 3 (6%) 3 (6%) 3 (6%) 1 (2%) Mesothelioma Malignant 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 12 NTP Experiment-Test: 55301-04 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC PYRIDINE Date: 11/19/96 Route: DOSED WATER Time: 15:36:01 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 43 49 48 47 Total Primary Neoplasms 79 122 122 114 Total Animals with Benign Neoplasms 35 42 36 39 Total Benign Neoplasms 51 53 49 54 Total Animals with Malignant Neoplasms 22 46 47 42 Total Malignant Neoplasms 28 69 73 60 Total Animals with Metastatic Neoplasms 8 12 19 14 Total Metastatic Neoplasm 8 30 35 30 Total Animals with Malignant Neoplasms 1 Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 13 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------